SCHEMBL8784135

SCHEMBL8784135

Cc1ccnc2c1CCCC2O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UGT2B17 O75795 2/20 0.42
ACHE P22303 1/20 0.41
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
BRD3 Q15059 1/20 0.35
CYP11B1 P15538 2/20 0.32
CYP11B2 P19099 2/20 0.32
CCR1 P32246 1/20 0.31
CCR5 P51681 1/20 0.31
CCR8 P51685 1/20 0.31
NOS3 P29474 3/20 0.31
NOS2 P35228 3/20 0.31
NOS1 P29475 1/20 0.31
EPAS1 Q99814 1/20 0.31
HRH2 P25021 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
OPRL1 P41146 3/20 0.30
KCNH2 Q12809 3/20 0.30
P2RX7 Q99572 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30640696 1.00 UGT2B17 (0.42) UGT2B17ACHEHTR2AHTR2CHTR2B
SCHEMBL10286119 0.95 UGT2B17 (0.38) UGT2B17ACHEHTR2AHTR2CHTR2B
SCHEMBL13270953 0.91 HTR2A (0.39) UGT2B17ACHEHTR2AHTR2CHTR2B
SCHEMBL10287354 0.82 ACHE (0.41) UGT2B17ACHEBRD3CYP11B1CYP11B2
SCHEMBL14885012 0.81 HTR2A (0.39) UGT2B17ACHEHTR2AHTR2CHTR2B
SCHEMBL30983298 0.81 ACHE (0.40) UGT2B17ACHEHTR2AHTR2CHTR2B
SCHEMBL8263282 0.81 ACHE (0.40) UGT2B17ACHEHTR2AHTR2CHTR2B
SCHEMBL30666726 0.81 ACHE (0.43) UGT2B17ACHEHTR2AHTR2CHTR2B
SCHEMBL10287419 0.80 HTR2A (0.39) UGT2B17ACHEHTR2AHTR2CHTR2B
SCHEMBL4066377 0.80 ADRA1A (0.43) UGT2B17ACHEHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035379-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2026-02-05 US disclosed
US-12534475-B2 Bicyclic pyridine derivative Sumitomo Pharma Co., Ltd. (JP) 2026-01-27 US disclosed
US-12077546-B2 Bicyclic pyridine derivative Sumitomo Pharma Co., Ltd. (JP) 2024-09-03 US disclosed
US-20240228505-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2024-07-11 US disclosed
US-20240150370-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2024-05-09 US disclosed
EP-4324834-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2024-02-21 EP disclosed
CN-117177977-A Bicyclic pyridine derivatives 住友制药株式会社 2023-12-05 CN disclosed
WO-2022215754-A1 BICYCLIC PYRIDINE DERIVATIVE 住友ファーマ株式会社 2022-10-13 WO disclosed
US-20130102631-A1 NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES SYNGENTA CROP PROTECTION LLC (US) 2013-04-25 US disclosed
US-20130102631-A1 NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES SYNGENTA CROP PROTECTION LLC (US) 2013-04-25 US disclosed
WO-2012001040-A1 NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2012-01-05 WO disclosed
US-20110059939-A1 THERAPEUTIC COMPOUNDS ALLERGAN ,INC (US) 2011-03-10 US disclosed
EP-0395244-B1 Pyridine derivatives WYETH JOHN & BROTHER LTD (GB) 1997-02-19 EP disclosed
US-5194439-A 5-HT Agonists or Antagonists, Nervous System Disorders, Hypotensive Agents JOHN WYETH & BROTHER LIMITED (GB) 1993-03-16 US disclosed
US-5075303-A Central nervous system disorders JOHN WYETH & BROTHER LIMITED (GB) 1991-12-24 US disclosed
EP-0395244-A1 Pyridine derivatives JOHN WYETH & BROTHER LIMITED (GB) 1990-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059939-A1 THERAPEUTIC COMPOUNDS CYP11B1, CYP11B2, SLC10A2 UGT2B17 355/4885ACHE 618/4885HTR2A 3424/4885
US-20260035379-A1 BICYCLIC PYRIDINE DERIVATIVE CBR1, CBR3, CYP2B6 UGT2B17 752/4885ACHE 3973/4885HTR2A 642/4885
US-20240228505-A1 BICYCLIC PYRIDINE DERIVATIVE CBR1, CBR3, CYB5R3 UGT2B17 1003/4885ACHE 3607/4885HTR2A 1075/4885
US-12077546-B2 Bicyclic pyridine derivative CBR1, CBR3, CYB5R3 UGT2B17 1003/4885ACHE 3607/4885HTR2A 1075/4885
US-20240150370-A1 BICYCLIC PYRIDINE DERIVATIVE CBR1, CBR3, CYB5R3 UGT2B17 1003/4885ACHE 3607/4885HTR2A 1075/4885
US-20130102631-A1 NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES MSR1, DDT, MPO UGT2B17 1446/4885ACHE 660/4885HTR2A 3575/4885
US-12534475-B2 Bicyclic pyridine derivative CBR1, CYP2B6, CBR3 UGT2B17 468/4885ACHE 4482/4885HTR2A 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.